Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain During the Membrane Fusion Process
Lu,Yun Zhu,Jinghe Huang,Xi Chen,Hengwen Yang,Shibo Jiang,Yinghua Chen
DOI: https://doi.org/10.1074/jbc.m801083200
IF: 5.485
2008-01-01
Journal of Biological Chemistry
Abstract:HIV-1 gp41 cytoplasmic tail (CT) is highly conserved among HIV-1 isolates, particularly the region designated lentivirus lytic peptide (LLP1–2), which includes two α-helical domains LLP1 and LLP2. Although the gp41 CT is recognized as a modulator of viral fusogenicity, little is known about the regulatory mechanism of this region in the viral fusion process. Here we report that anti-LLP1–2 and anti-LLP2 antibodies (IgG) inhibited HIV-1 Env-mediated cell fusion and bound to the interface between effector and target cells at a suboptimal temperature (31.5 °C), which slows down the fusion process and prolongs the fusion intermediate state. This suggests that LLP1–2, especially the LLP2 region located inside the viral membrane, is transiently exposed on the membrane surface during the fusion process. Synthetic LLP2 peptide could bind to the gp41 six-helix bundle core with high binding affinity. These results suggest that the gp41 CT may interact with the gp41 core, via the surface-exposed LLP2 domain, to regulate Env-mediated membrane fusion. HIV-1 gp41 cytoplasmic tail (CT) is highly conserved among HIV-1 isolates, particularly the region designated lentivirus lytic peptide (LLP1–2), which includes two α-helical domains LLP1 and LLP2. Although the gp41 CT is recognized as a modulator of viral fusogenicity, little is known about the regulatory mechanism of this region in the viral fusion process. Here we report that anti-LLP1–2 and anti-LLP2 antibodies (IgG) inhibited HIV-1 Env-mediated cell fusion and bound to the interface between effector and target cells at a suboptimal temperature (31.5 °C), which slows down the fusion process and prolongs the fusion intermediate state. This suggests that LLP1–2, especially the LLP2 region located inside the viral membrane, is transiently exposed on the membrane surface during the fusion process. Synthetic LLP2 peptide could bind to the gp41 six-helix bundle core with high binding affinity. These results suggest that the gp41 CT may interact with the gp41 core, via the surface-exposed LLP2 domain, to regulate Env-mediated membrane fusion. It is generally agreed that the human immunodeficiency virus (HIV) 4The abbreviations used are: HIV, human immunodeficiency virus; HIV-1, HIV type 1; CT, cytoplasmic tail; NHR, N-terminal heptad repeat; CHR, C-terminal heptad repeat; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; SPR, surface plasmon resonance; TBS, Tris buffered solution; GMEM, glutamine-deficient minimal essential medium; 6-HB, six-helix bundle; mAb, monoclonal antibody; aa, amino acid. 4The abbreviations used are: HIV, human immunodeficiency virus; HIV-1, HIV type 1; CT, cytoplasmic tail; NHR, N-terminal heptad repeat; CHR, C-terminal heptad repeat; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; SPR, surface plasmon resonance; TBS, Tris buffered solution; GMEM, glutamine-deficient minimal essential medium; 6-HB, six-helix bundle; mAb, monoclonal antibody; aa, amino acid. envelope glycoprotein (Env) transmembrane subunit gp41 plays an essential role during viral infection by mediating membrane fusion. Based on the crystal structure of the gp41 core, Chan et al. (1Chan D.C. Fass D. Berger J.M. Kim P.S. Cell. 1997; 89: 263-273Abstract Full Text Full Text PDF PubMed Scopus (1833) Google Scholar, 2Chan D.C. Kim P.S. Cell. 1998; 93: 681-684Abstract Full Text Full Text PDF PubMed Scopus (1110) Google Scholar) have proposed a membrane fusion model for HIV-1 entry. In this model, the Env surface subunit gp120 binds to both CD4 and the chemokine receptor (CCR5 or CXCR4) on the target cells to trigger a conformational change of gp41, i.e. association between its N- and C-terminal heptad repeats (NHR and CHR, respectively) to form a six-helix bundle (6-HB), which is thought to bring the membranes of both virus and target cells into close proximity for facilitating membrane fusion (1Chan D.C. Fass D. Berger J.M. Kim P.S. Cell. 1997; 89: 263-273Abstract Full Text Full Text PDF PubMed Scopus (1833) Google Scholar, 3Weissenhorn W. Dessen A. Harrison S.C. Skehel J.J. Wiley D.C. Nature. 1997; 387: 426-430Crossref PubMed Scopus (1459) Google Scholar, 4Tan K. Liu J. Wang J. Shen S. Lu M. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 12303-12308Crossref PubMed Scopus (518) Google Scholar, 5Caffrey M. Cai M. Kaufman J. Stahl S.J. Wingfield P.T. Covell D.G. Gronenborn A.M. Clore G.M. EMBO J. 1998; 17: 4572-4584Crossref PubMed Scopus (369) Google Scholar, 6Pascual R. Moreno M.R. Villalain J. J. Virol. 2005; 79: 5142-5152Crossref PubMed Scopus (43) Google Scholar). However, the events following 6-HB formation prior to completion of the fusion process are unclear, and the regulation of the fusion process remains to be elucidated. By using suboptimal temperature (31.5 °C) to slow down the fusion process, Golding et al. (7Golding H. Zaitseva M. de Rosny E. King L.R. Manischewitz J. Sidorov I. Gorny M.K. Zolla-Pazner S. Dimitrov D.S. Weiss C.D. J. Virol. 2002; 76: 6780-6790Crossref PubMed Scopus (116) Google Scholar) have shown that the anti-bundle specific antibodies could bind to the 6-HB located between effector and target cells and block virus-cell and cell-cell fusion. These results suggest that 6-HBs are formed prior to membrane fusion, and after drawing the viral and target cell membranes together, they may perform additional functions in the late stage of membrane fusion. Meanwhile, apart from the important documented roles of the NHR, CHR, and the 6-HB in fusion reactivity, completion of the entire fusion process may also require the involvement of other regions in gp41, such as the membrane-spanning domain (aa 666–682 of the HXB2 strain of HIV-1) and the gp41 cytoplasmic tail (CT) (8Dimitrov A.S. Jacobs A. Finnegan C.M. Stiegler G. Katinger H. Blumenthal R. Biochemistry. 2007; 46: 1398-1401Crossref PubMed Scopus (74) Google Scholar, 9Hunter E. Swanstrom R. Curr. Top. Microbiol. Immunol. 1990; 157: 187-253PubMed Google Scholar, 10Wyss S. Dimitrov A.S. Baribaud F. Edwards T.G. Blumenthal R. Hoxie J.A. J. Virol. 2005; 79: 12231-12241Crossref PubMed Scopus (104) Google Scholar). As members of the lentiviruses, HIV-1, HIV-2, and simian immunodeficiency virus have a relatively long cytoplasmic tail (CT) (∼150 amino acids), compared with other retroviruses with cytoplasmic domains consisting of only 20–30 amino acids (9Hunter E. Swanstrom R. Curr. Top. Microbiol. Immunol. 1990; 157: 187-253PubMed Google Scholar). The HIV-1 gp41 CT consists of the "Kennedy" polypeptide sequence (aa 731–752) and the lentivirus lytic peptide (LLP1–2, aa 773–862), which contains three highly conserved α-helix domains as follows: LLP1 (aa 833–862), LLP2 (aa 773–793), and LLP3 (aa785–807) (11Miller M.A. Garry R.F. Jaynes J.M. Montelaro R.C. AIDS Res. Hum. Retroviruses. 1991; 7: 511-519Crossref PubMed Scopus (97) Google Scholar). The HIV-1 gp41 CT has many functions, including interaction with the plasma membrane, decrease of bilayer stability, alteration of membrane ionic permeability, and mediation of cell killing (10Wyss S. Dimitrov A.S. Baribaud F. Edwards T.G. Blumenthal R. Hoxie J.A. J. Virol. 2005; 79: 12231-12241Crossref PubMed Scopus (104) Google Scholar, 12Chen S.S. Lee S.F. Wang C.T. J. Virol. 2001; 75: 9925-9938Crossref PubMed Scopus (43) Google Scholar, 13Chernomordik L. Chanturiya A.N. Suss-Toby E. Nora E. Zimmerberg J. J. Virol. 1994; 68: 7115-7123Crossref PubMed Google Scholar, 14Comardelle A.M. Norris C.H. Plymale D.R. Gatti P.J. Choi B. Fermin C.D. Haislip A.M. Tencza S.B. Mietzner T.A. Montelaro R.C. Garry R.F. AIDS Res. Hum. Retroviruses. 1997; 13: 1525-1532Crossref PubMed Scopus (36) Google Scholar, 15Kalia V. Sarkar S. Gupta P. Montelaro R.C. J. Virol. 2003; 77: 3634-3646Crossref PubMed Scopus (62) Google Scholar, 16Kliger Y. Shai Y. Biochemistry. 1997; 36: 5157-5169Crossref PubMed Scopus (65) Google Scholar). Recent studies have shown that the gp41 CTs of HIV and simian immunodeficiency virus correlate with their infectivity and Env-mediated cell-cell fusion (10Wyss S. Dimitrov A.S. Baribaud F. Edwards T.G. Blumenthal R. Hoxie J.A. J. Virol. 2005; 79: 12231-12241Crossref PubMed Scopus (104) Google Scholar, 15Kalia V. Sarkar S. Gupta P. Montelaro R.C. J. Virol. 2003; 77: 3634-3646Crossref PubMed Scopus (62) Google Scholar). The mutations or truncations of gp41 CT can affect HIV-1 Env-mediated cell-cell fusion, presumably because of modulation of the fusogenicity of Env (17Edwards T.G. Wyss S. Reeves J.D. Zolla-Pazner S. Hoxie J.A. Doms R.W. Baribaud F. J. Virol. 2002; 76: 2683-2691Crossref PubMed Scopus (152) Google Scholar, 18Zingler K. Littman D.R. J. Virol. 1993; 67: 2824-2831Crossref PubMed Google Scholar). Kalia et al. (15Kalia V. Sarkar S. Gupta P. Montelaro R.C. J. Virol. 2003; 77: 3634-3646Crossref PubMed Scopus (62) Google Scholar) discovered that one Env having a mutation in the gp41 CT LLP2 region (MX2) exhibited a decrease of about 90% in fusogenicity compared with the wild-type Env and that the mutation did not correspond to apparent defects in the levels of cell surface Env expression. However, in some other studies, certain point mutations and particularly truncations of gp41 CT were shown to induce faster fusion kinetics (19Abrahamyan L.G. Mkrtchyan S.R. Binley J. Lu M. Melikyan G.B. Cohen F.S. J. Virol. 2005; 79: 106-115Crossref PubMed Scopus (74) Google Scholar, 20Gabuzda D.H. Lever A. Terwilliger E. Sodroski J. J. Virol. 1992; 66: 3306-3315Crossref PubMed Google Scholar, 21Spies C.P. Compans R.W. Virology. 1994; 203: 8-19Crossref PubMed Scopus (69) Google Scholar, 22Wilk T. Pfeiffer T. Bosch V. Virology. 1992; 189: 167-177Crossref PubMed Scopus (140) Google Scholar). Recently, Wyss et al. (10Wyss S. Dimitrov A.S. Baribaud F. Edwards T.G. Blumenthal R. Hoxie J.A. J. Virol. 2005; 79: 12231-12241Crossref PubMed Scopus (104) Google Scholar) have also demonstrated that the gp41 CT LLP2 domain restricted Env fusogenicity during Env processing, as did the murine leukemia viruses, where cleavage of a membrane-interactive R peptide at the C terminus is required for Env to become fusogenic. Although the combined data imply that gp41 CT could affect cell-cell fusion, this mechanism also remains vague and controversial. Therefore, further study of the characteristics of gp41 CT is warranted, especially that of its added effect on Env-mediated fusion reactivity. It is generally believed that the entire gp41 CT is located inside the cell. However, existing experimental and computational evidence suggest that the Kennedy sequence might lie outside the cell, because the antibodies against the Kennedy sequence can bind to virus-infected cells and neutralize HIV-1 infectivity (23Cleveland S.M. McLain L. Cheung L. Jones T.D. Hollier M. Dimmock N.J. J. Gen. Virol. 2003; 84: 591-602Crossref PubMed Scopus (46) Google Scholar, 24Kennedy R.C. Henkel R.D. Pauletti D. Allan J.S. Lee T.H. Essex M. Dreesman G.R. Science. 1986; 231: 1556-1559Crossref PubMed Scopus (127) Google Scholar). Our study focuses on the gp41 CT LLP1–2 region, especially the LLP1 and LLP2 regions that have been directly proven to be associated with the membrane fusion process (10Wyss S. Dimitrov A.S. Baribaud F. Edwards T.G. Blumenthal R. Hoxie J.A. J. Virol. 2005; 79: 12231-12241Crossref PubMed Scopus (104) Google Scholar, 15Kalia V. Sarkar S. Gupta P. Montelaro R.C. J. Virol. 2003; 77: 3634-3646Crossref PubMed Scopus (62) Google Scholar), and aims to determine whether LLP1–2 directly or indirectly participates in the fusion reaction and, if so, to understand the underlying mechanism(s) of this event. Here we report, for the first time, that during the HIV-1 fusion process, the LLP1–2 region of gp41 CT, in particular the LLP2 domain, may be transiently exposed on the surface of the effector cell in the presence of the target cell. Synthetic peptide derived from the LLP2 sequence could interact with the gp41 6-HB core. These results suggest that gp41 CT may regulate the fusogenicity of viral Env through the interaction of the transiently exposed LLP2 region with the gp41 core on virions or HIV-1-infected cells. Cell Lines and Animals—3T3 cells stably expressing CD4 and CXCR4 (3T3-T4-CXCR4) were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 100 IU/ml of penicillin and streptomycin. CHO cells stably transfected with HIV-1 (HXB2) Env expressing vector pEE 14 (designated CHO-WT) or control pEE 14 vector (designated CHO-EE) were cultured in glutamine-deficient minimal essential medium (GMEM-S) containing 400 μm methionine sulfoximine (Sigma). Expression and Purification of gp41 CT Fragments—The gp41 CT fragments LLP1–2, LLP1, and LLP2 (Fig. 1) were expressed in Escherichia coli using the plasmids pGEX-6p-1-LLP1–2, pGEX-6p-1-LLP1, and pGEX-6p-1-LLP2, respectively, as described previously (25Zhu Y. Lu L. Chao L. Chen Y.H. Chem. Biol. Drug Des. 2007; 70: 311-318Crossref PubMed Scopus (9) Google Scholar). The polypeptide N36-L8-C34, its mutants, and 3NC were constructed and expressed as described previously (26Huang J.H. Liu Z.Q. Liu S. Jiang S. Chen Y.H. FEBS Lett. 2006; 580: 4807-4814Crossref PubMed Scopus (17) Google Scholar, 27Qiao Z.S. Kim M. Reinhold B. Montefiori D. Wang J.H. Reinherz E.L. J. Biol. Chem. 2005; 280: 23138-23146Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar, 28Root M.J. Kay M.S. Kim P.S. Science. 2001; 291: 884-888Crossref PubMed Scopus (379) Google Scholar), and further purified by anion-exchange Q column (GE Healthcare). Peptide LLP2 was synthesized by a standard solid phase Fmoc (N-(9-fluorenyl)methoxycarbonyl) method and purified to homogeneity (>95% purity) by high pressure liquid chromatography. Production and Detection of Anti-gp41 CT Polyclonal Antibodies—New Zealand White rabbits (1.7–1.9 kg) were immunized subcutaneously with a dose of 100 μg of purified recombinant protein LLP1–2 or peptide LLP2 in complete Freund's adjuvant and boosted three times at 2-week intervals with an identical dose of LLP1–2 or LLP2 in incomplete Freund's adjuvant. Rabbit antisera were collected, and the anti-LLP1–2 and anti-LLP2 IgG were purified with protein G affinity column (GE Healthcare), from which LLP1–2-, LLP1-, and LLP2-specific IgG were further isolated using N-hydroxysuccinimide-activated Sepharose 4 Fast Flow beads (GE Healthcare) conjugated with the corresponding proteins or peptides, respectively. The flow-through fractions were also collected as controls. Antibody concentrations were established by spectrophotometry. HIV-1 Env-mediated Cell-Cell Fusion Assay—Wells of a 96-well plate were coated with 1 × 106 3T3 cells stably expressing CD4 and CXCR4 (3T3-T4-CXCR4) and incubated overnight at 37 °C. Simultaneously, CHO-WT cells were pre-stimulated with 7 mm sodium butyrate for about 20 h and then 2×104 cells per well were added in the absence or presence of anti-gp41 CT-specific IgG or normal rabbit IgG. After coculturing for 6 h at 5% CO2, 31.5 °C, the plate was gently transferred to a 5% CO2, 37 °C environment. After a further 9–16 h, syncytia were counted under a microscope. The percentage of inhibition of syncytium formation was calculated using the following formula: % inhibition = (1 - (number of syncytia in a well containing an inhibitor)/number of syncytia in a well containing no inhibitor) × 100. Flow Cytometry Assay—CHO-WT cells or a mixture of CHO-WT cells and 3T3-T4-CXCR4 cells (1 × 105) were incubated with anti-gp41 CT-specific IgG or normal rabbit IgG in a 50-μl final volume at 31.5 °C for 2 h in GMEM containing 2% goat serum. Then the mixtures were transferred onto ice for 1 h. After thorough washing with TBS and 2% goat serum (pH 7.4), cells were incubated with FITC-conjugated goat anti-rabbit IgG (Dako, 1:40 dilution in TBS with 2% goat serum) for 1 h on ice. Finally, the mixtures were washed three times using 200 μl of TBS with 2% goat serum and subsequently analyzed in a FACSCalibur (BD Biosciences) with CellQuest™ software (BD Biosciences). Immunofluorescence—To observe binding of LLP1–2- and LLP2-specific IgG to fusion intermediates, Env-expressing CHO-WT and 3T3-T4-CXCR4 cells, respectively, were blocked with blocking buffer (2% normal goat serum in TBS) for 30 min at 31.5 °C, followed by incubation with rabbit LLP1–2-specific IgG, LLP2-specific IgG, or normal rabbit IgG (50 μg/ml) for 2 h at 31.5 °C in GMEM containing 2% goat serum. Then the cells were immediately placed on ice for 1 h. After the cells were harvested, they were washed twice with ice-cold blocking buffer and incubated with FITC-conjugated goat anti-rabbit IgG (Dako, 1:40 dilution in TBS with 2% goat serum). Finally, the cells were washed again, fixed, applied to poly-l-lysine-coated glass slides, mounted, and observed under the confocal microscope. Enzyme-linked Immunosorbent Assay (ELISA)—To determine the specific antibody binding to the gp41 CT fragments, ELISA was carried out as described previously (29Jiang S. Lin K. Zhang L. Debnath A.K. J. Virol. Methods. 1999; 80: 85-96Crossref PubMed Scopus (110) Google Scholar). Briefly, the respective recombinant proteins and peptides (50 μg/ml) dissolved in 0.1 m Tris (pH 8.8) were used to coat 96-well polystyrene plates, which were then blocked with Tris-buffered solution (pH 8.5) containing 0.25% gelatin and 0.1% Tween 20. After three washes with TBS (pH 7.4) containing 0.1% Tween 20 (TBS-T), the respective IgGs were added to the wells at the indicated concentrations. Then swine-anti-rabbit IgG and the substrate o-phenylenediamine were added sequentially. The absorbance at 450 nm (A450) was recorded with an ELISA reader. Each sample was tested in triplicate. Binding of the mAb NC-1 and the recombinant LLP1–2 and LLP2, respectively, to the peptides N36, C34, or the 6-HB modeled by N36/C34, N36-L8-C34, 3NC, and N36-L8-C34 mutants, was determined as described previously (30Huang J.H. Yang H.W. Liu S. Li J. Jiang S. Chen Y.H. Biochem. J. 2007; 403: 565-571Crossref PubMed Scopus (12) Google Scholar). Briefly, 96-well polystyrene plates were coated with 100 μl of LLP1–2 (20 μg/ml), LLP2 (20 μg/ml), NC-1 (2 μg/ml), or 0.25% gelatin (as a negative control), respectively, and blocked with TBS (pH 8.5) containing 0.25% gelatin and 0.1% Tween 20. After three washes, the N36/C34 mixture, the isolated N36 or C34 peptide (5 μg/ml for each peptide) (Fig. 5A, panel a), recombinant N36-L8-C34 and 3NC at indicated concentrations (Fig. 5A, panel b), and N36-L8-C34 mutants (5 μg/ml) (Fig. 7A) were added, respectively. After incubation at 37 °C for 45 min, rabbit anti-N36/C34 IgG, which can recognize both the individual peptides N36 and C34 and 6-HBs, peroxidase-conjugated anti-rabbit IgG and substrate o-phenylenediamine were added sequentially. Absorbance (A450) values were recorded. The relative binding activity (%) of the N36-L8-C34 (NC) mutants to LLP2 peptide was calculated on the basis that the binding activity of the wild-type N36-L8-C34 (NC WT) to LLP2 peptide equals 100% (Fig. 7A).FIGURE 7A, relative binding activity of 6-HBs formed by N36-L8-C34 (NC) and its mutants to the synthetic peptide LLP2. Each mutant of 6-HB bears a single Ala or Val substitution at the b, c, and f positions of the helix wheels of the N- and C-helices in 6-HB. The binding activity was detected by ELISA. The data represent triplicate determinations that were performed at least three times. All results are presented as mean ± S.D. B, schematic shows the potential binding sites of LLP2 in gp41 6-HB.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Surface Plasmon Resonance (SPR) Assay—The kinetics of the binding affinity of the gp41 CT LLP1–2 and LLP2 to gp41 core modeled by recombinant protein 3NC was determined by SPR using the Biacore system (GE Healthcare) according to the biomolecular interaction analysis (BIA) technology manual. In brief, the CM5 sensor chip was immobilized with 3NC (100 μg/ml) by amine coupling, and the unreacted sites were blocked with ethanolamine. The association reaction was initiated by injecting 40 μl of polypeptide LLP1–2 or LLP2 in HEPES buffer (pH 7.4) with 0.05% Triton X-100 at a flow rate of 20 μl/min. The dissociation reaction was done by washing with running buffer (10 mm HEPES (pH 7.4) containing 0.15 m NaCl, 3.4 mm EDTA and 0.005% v/v surfactant P20). At the end of the cycle, the sensor chip surface was regenerated with 10 mm HCl for 30 s. The association (Kon) and dissociation (Koff) rate constants were estimated from the response curve, and the dissociation equilibrium constant (Kd) was calculated using the following equation: Kd = Koff/Kon, as described previously (31Huang J.H. Lu L. Lu H. Chen X. Jiang S. Chen Y.H. J. Biol. Chem. 2007; 282: 6143-6152Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Isolation and Characterization of Antibodies Specific for the gp41 CT Fragments LLP1–2, LLP1, and LLP2—The gp41 CT fragment LLP1–2, expressed in E. coli using the plasmids pGEX-6p-1, and the synthetic peptide LLP2 were used for immunization of rabbits. Anti-LLP1–2 and anti-LLP2 IgG, respectively, were purified from the rabbit antisera with protein G affinity column (GE Healthcare). Then LLP1–2-, LLP1-, and LLP2-specific IgG were isolated from anti-LLP1–2 and anti-LLP2 IgG using the GST-LLP1–2-, GST-LLP1-, and GST-LLP2-bound N-hydroxysuccinimide-activated Sepharose (4 Fast Flow, GE Healthcare), respectively. The flow-through fractions from LLP1–2- and LLP2-bound Sepharose 4 were collected as LLP1–2-specific IgG-depleted anti-LLP1–2 IgG (designated anti-LLP1–2 IgG/LLP1–2) and LLP2-specific IgG-depleted anti-LLP1–2 IgG (designated anti-LLP1–2 IgG/LLP2), respectively. The binding specificity of the IgG obtained was determined by ELISA. As shown in Fig. 2A, LLP1–2-specific IgG bound with LLP1–2, GST-LLP1, and GST-LLP2. LLP1-specific IgG reacted with both LLP1–2 and GST-LLP1 but did not interact with GST-LLP2, whereas LLP2-specific IgG bound to both LLP1–2 and GST-LLP2 but did not recognize GST-LLP1. These results verify the specificity of the antibodies directed against the corresponding gp41 CT fragments. No LLP1–2- and LLP2-specific IgGs were detected in the flow-through fractions from the Sepharose 4B columns conjugated with LLP1–2 (anti-LLP1–2 IgG/LLP1–2) and LLP2 (anti-LLP1–2 IgG/LLP2), respectively, suggesting that the corresponding IgGs were depleted from the anti-LLP1–2 IgG fraction. Interestingly, LLP2-specific IgG predominated over the LLP1-specific IgG in the anti-LLP1–2 IgG (data not shown). In the next step, the LLP1–2- and LLP2-specific antibodies were used for detecting the potential interaction of the gp41 CT fragments with the peptides derived from the gp41 NHR or CHR or 6-HB. To exclude the possibility of the anti-gp41 CT antibodies binding nonspecifically to the extracellular domain of gp41, an ELISA was performed. As shown in Fig. 2B, anti-LLP1–2 and anti-LLP2 IgGs only recognize LLP1–2 and LLP2 but did not react with the rsgp41, nor with the peptides N36 and C34 as well as the 6-HB formed by N36/C34, confirming that anti-gp41 CT antibodies do not cross-react with the gp41 ectodomain. Binding of Anti-gp41 CT Antibodies to the Effector Cells in the Presence of Target Cells at Suboptimal Temperature—It was reported previously that the main part of the gp41 CT, i.e. the LLP1–2 region, is hidden within the HIV-1 virion (32Wyma D.J. Kotov A. Aiken C. J. Virol. 2000; 74: 9381-9387Crossref PubMed Scopus (139) Google Scholar) and cannot be recognized by the antibodies specific for the gp41 CT sequences (aa 799–817 and 844–863) (23Cleveland S.M. McLain L. Cheung L. Jones T.D. Hollier M. Dimmock N.J. J. Gen. Virol. 2003; 84: 591-602Crossref PubMed Scopus (46) Google Scholar). However, we believe that part of the gp41 LLP1–2 region may be exposed on the cell surface during the membrane fusion process, interacting with the extracellular domain of gp41, thus regulating viral fusogenicity via the "insideout" signaling pathway. To determine the potential exposure of gp41 CT fragments, flow cytometry assay was performed to detect the binding of LLP1–2-, LLP1-, and LLP2-specific IgG to the effector (E) cells that express HIV-1 Env (CHO-WT cells) in the absence or presence of the target (T) cells, which express CD4 and the coreceptor CXCR4 (3T3-T4-CXCR4 cells), at a physiological temperature (37 °C) or a suboptimal temperature (31.5 °C). The results show that LLP1–2-specific IgG did not bind to effector cells in the absence of target cells at 37 °C (data not shown) nor at 31.5 °C (Fig. 3A, panel a). This antibody was also unable to bind to effector cells in the presence of target cells at 37 °C (Fig. 3A, panel b). However, both LLP1–2- and LLP2-specific IgG bound significantly with the effector cells in the presence of target cells at 31.5 °C (Fig. 3A, panel c). In contrast, the LLP1-specific IgG and the LLP2-specific IgG-depleted anti-LLP1–2 IgG (anti-LLP-12 IgG/LLP2) were incapable of binding to effector cells under the same conditions (Fig. 3A, panel c). These results suggest that the LLP2, and not the LLP1 domain in the gp41 CT LLP1–2 region, may be exposed on the surface of the effector cell when it interacts with the target cell for cell-to-cell fusion, resulting in binding of the anti-LLP2 antibody to the effector cell. However, this binding is only detectable when the effector cell interacts with the target cell at suboptimal temperature, which can prolong the fusion intermediate state. Otherwise, the antibody (IgG) may not have access to the narrow space of the interface between the effector and target cell during the conventional fusion process at physiological temperatures. This assumption is further supported by results from confocal microscopy analysis. At suboptimal temperature, normal rabbit IgG could not bind to effector cells in the presence of target cells (Fig. 3B, panel a). However, both LLP1–2-specific IgG (Fig. 3B, panel b) and LLP2-specific IgG (Fig. 3B, panel c) bound significantly to the interfaces of the effector/target cells. None of these antibodies bound to effector cells in the absence of target cells at either 37 or 31.5 °C, nor in the presence of target cells at 37 °C (data not shown). Inhibition of Env-mediated Cell Fusion by Anti-gp41 CT Antibodies at Suboptimal Temperature—We further hypothesized that during the membrane fusion process, the gp41 CT LLP2 domain may be transiently exposed on the surface of effector cells at a suboptimal temperature to interact with the extracellular domain for regulating viral fusogenicity. Binding of the anti-LLP2 antibodies to the exposed LLP2 domain may affect the membrane fusion process. Therefore, the inhibitory activity of antibodies against gp41 CT fragments on Env-mediated cell-to-cell fusion at physiological and suboptimal temperatures was determined by using a syncytium formation assay. As shown in Fig. 4A, both LLP1–2- and LLP2-specific IgG showed potent inhibitory activity against Env-mediated syncytium formation when effector and target cells were cocultured at a suboptimal temperature (31.5 °C), whereas normal rabbit IgG, LLP1-specific IgG, and the LLP2-specific IgG-depleted anti-LLP1–2 IgG (anti-LLP-1–2 IgG/LLP2) exhibited no significant inhibition of cell-cell fusion. However, none of the anti-gp41 CT antibodies could inhibit Env-mediated syncytium formation when effector and target cells were cocultured at 37 °C (Fig. 4B). This result suggests that the LLP1–2- and LLP2-specific IgG may bind to the LLP2 domain, which is transiently exposed on the effector cell surface during the interaction between effector and target cells, thereby interfering with gp41 CT-mediated cell-cell fusion. Similarly, the antibodies may not be able to access the E/T interface during interaction of effector cell with target cell at physiological temperatures, resulting in lack of cell-cell fusion inhibition. Interaction of LLP1–2 and LLP2 with gp41 6-HB Core—The next logical question is which molecule LLP1–2 or LLP2 will interact with after its surface exposure. We hypothesized that LLP1–2 or LLP2 may affect the HIV-1 Env-mediated membrane fusion by interacting with either the gp41 NHR or CHR region at an earlier stage or with the gp41 6-HB core at the later stage of cell-cell fusion. We thus tested whether LLP1–2 could bind to NHR-peptide N36, or CHR-peptide C34, or 6-HB core modeled by N36/C34. Surprisingly, recombinant protein LLP1–2 and synthetic peptide LLP2 strongly bound to the 6-HB core formed by the N36/C34 mixture, but exhibited no significant binding to the individual N36 and C34 peptides (Fig. 5A). To confirm binding between LLP2 (or LLP1–2) and the 6-HB core, we expressed and purified the polypeptides N36-L8-C34 (26Huang J.H. Liu Z.Q. Liu S. Jiang S. Chen Y.H. FEBS Lett. 2006; 580: 4807-4814Crossref PubMed Scopus (17) Google Scholar) and 3NC, which can automatically form 6-HBs in physiological solution (27Qiao Z.S. Kim M. Reinhold B. Montefiori D. Wang J.H. Reinherz E.L. J. Biol. Chem. 2005; 280: 23138-23146Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar, 28Root M.J. Kay M.S. Kim P.S. Science. 2001; 291: 884-888Crossref PubMed Scopus (379) Google Scholar). As shown in Fig. 5A, panel b, both the recombinant protein LLP1–2 and peptide LLP2 strongly bound to N36-L8-C34 and 3NC in a dose-dependent manner. In the real time SPR spectrum assay, similar results were obtained, i.e. both LLP1–2 (Fig. 5B, panel a) and LLP2 (Fig. 5B, panel b) bound to 3NC in a dose-dependent manner with high binding affinity. However, the data did not fit the 1:1 Langmuir binding and other existing models, which may be attributed to the fact that N36-L8-C34 and 3NC form typical 6-HBs in physiological solution (26Huang J.H. Liu Z.Q. Liu S
What problem does this paper attempt to address?
-
Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors
Jing Li,Xi Chen,Jinghe Huang,Shibo Jiang,Ying-Hua Chen
DOI: https://doi.org/10.1016/j.imbio.2008.04.005
IF: 3.152
2009-01-01
Immunobiology
Abstract:Formation of the six-helix bundle (6-HB) core between the N- and C-terminal heptad repeats (NHR and CHR) regions of the HIV-1 envelope glycoprotein (Env) transmembrane subunit gp41 is a critical step during the process of virus and target cell membrane fusion. In the present study, we generated a panel of five monoclonal antibodies (mAbs) which specifically recognized the HIV-1 gp41 6-HB formed by the NHR-peptide N36 and CHR-peptide C34 mixture, but did not react with the isolated peptides N36 and C34. These mAbs did not block the HIV-1 Env-mediated cell–cell fusion at physiological temperature (37°C), but inhibited the HIV-1 Env-mediated cell–cell fusion at suboptimal temperature (31.5°C), under which condition the fusion process is slowed down and the viral 6-HB becomes accessible. The fusion inhibitory activity of the mAbs is correlated with their binding affinity with the 6-HB core. By screening 24 6-HB variants with single mutations at the b, c, and f positions in the helical wheels, we found that the critical binding sites of these mAbs were localized in the N-terminal region of the NHR and the C-terminal region of the CHR. These sites may serve as targets for design of small molecule HIV fusion inhibitors, e.g., organic compounds, peptides, and low molecular weight proteins.
-
Maturation-Dependent Human Immunodeficiency Virus Type 1 Particle Fusion Requires a Carboxyl-Terminal Region of the Gp41 Cytoplasmic Tail
Jiyang Jiang,Christopher Aiken
DOI: https://doi.org/10.1128/jvi.00592-07
IF: 6.549
2007-01-01
Journal of Virology
Abstract:Lentiviruses, including human immunodeficiency virus type 1 (HIV-1), typically encode fusion glycoproteins with long cytoplasmic tails (CTs). We previously reported that immature HIV-1 particles are inhibited for fusion with target cells by a mechanism requiring the 152-amino-acid CT of gp41. The gp41 CT was also shown to mediate the detergent-resistant association of the HIV-1 envelope glycoprotein complex with immature HIV-1 particles, indicating that the gp41 CT forms a stable complex with Gag in immature virions. In the present study, we analyzed the effects of progressive truncations and point mutations in the gp41 CT on the fusion of mature and immature HIV-1 particles with target cells. We also determined the effects of these mutations on the detergent-resistant association of gp41 with immature HIV-1 particles. Removal of the C-terminal 28 amino acids relieved the dependence of HIV-1 fusion on maturation. However, a mutant Env protein lacking this region remained associated with immature HIV-1 particles treated with nonionic detergent. Further mutational analysis of the C-terminal region of gp41 revealed two specific sequences required for maturation-dependent HIV-1 fusion. Collectively, our results demonstrate that the extreme C terminus of gp41 plays a key role in coupling HIV-1 fusion competence to virion maturation. They further indicate that the stable association of gp41 with Gag in immature virions is not sufficient for inhibition of immature HIV-1 particle fusion.
-
Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41
Renee Hrin,Donna L. Montgomery,Fubao Wang,Jon H. Condra,Zhiqiang An,William R. Strohl,Elisabetta Bianchi,Antonello Pessi,Joseph G. Joyce,Ying-Jie Wang
DOI: https://doi.org/10.1089/aid.2008.0129
2008-01-01
Abstract:Class 1 and class 2 fusion peptides bind to the trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR) regions of HIV-1 envelope glycoprotein gp41, respectively, and block its intramolecular folding required for Env-mediated viral and host cell membrane fusion and subsequent viral entry. Using a combination of T-20 (class 1) and (CCIZN17)(3) (class 2), we provide evidence that these classes of fusion peptides work synergistically in an in vitro infectivity assay in inhibiting the entry of primary HIV-1 isolate 89.6 with combination indexes reaching 0.37 and 0.32 at IC(50) and IC(90), respectively. We further demonstrate a similar degree of neutralization synergy between a monoclonal antibody (MAb), D5, targeting the hydrophobic pocket region of the NHR, and 2F5, a well-characterized MAb that targets the C-terminal end of CHR and the membrane-proximal external region (MPER), providing a rational basis for developing combination vaccines targeting these two highly conserved regions of gp41.
-
Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors
Yuxian He,Jianwei Cheng,Jingjing Li,Zhi Qi,Hong Lu,Mingxin Dong,Shibo Jiang,Qiuyun Dai
DOI: https://doi.org/10.1128/JVI.00319-08
IF: 6.549
2008-01-01
Journal of Virology
Abstract:Human immunodeficiency virus type 1 (HIV-1) entry into the host cell involves a cascade of events and currently represents one of most attractive targets in the search for new antiviral drugs. The fusion-active gp41 core structure is a stable six-helix bundle (6-HB) folded by its trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR). Peptides derived from the CHR region of HIV-1 gp41 are potent fusion inhibitors that target the NHR to block viral and cellular membrane fusion in a dominant negative fashion. However, all CHR peptides reported to date are derived primarily from residues 628 to 673 of gp41; little attention has been paid to the upstream sequence of the pocket binding domain (PBD) in the CHR. Here, we have identified a Motif ((621)QIWNNMT(627)) located at the upstream region of the gp41 CHR, immediately adjacent to the PBD ((WMEWEREI635)-W-628). Biophysical characterization demonstrated that this motif is critical for the stabilization of the gp41 6-HB core. The peptide CP621-652, containing the (621)QIWNNMT(627) motif, was able to interact with T21, a counterpart peptide derived from the NHR, to form a typical 6-HB structure with a high thermostability (thermal unfolding transition [T-m] value of 82 degrees C). In contrast, the 6-HB formed by the peptides N36 and C34, which has been considered to be a core structure of the fusion-active gp41, had a T-m of 64 degrees C. Different from T-20 (brand name Fuseon), which is the first and only HIV-1 fusion inhibitor approved for clinical use, CP621-652 could efficiently block 6-HB formation in a dose-dependent manner. Significantly, CP621-652 had potent inhibitory activity against HIV-1-mediated cell-cell fusion and infection, especially against T-20- and C34-resistant virus. Therefore, our works provide important information for understanding the core structure of the fusion-active gp41 and for designing novel anti-HIV peptides.
-
Residues in the Gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by Gp120-Directed Inhibitors.
Beatriz Pacheco,Nirmin Alsahafi,Olfa Debbeche,Jeremie Prevost,Shilei Ding,Jean-Philippe Chapleau,Alon Herschhorn,Navid Madani,Amy Princiotto,Bruno Melillo,Christopher Gu,Xin Zeng,Youdong Mao,Amos B. Smith,Joseph Sodroski,Andres Finzi
DOI: https://doi.org/10.1128/jvi.02219-16
IF: 6.549
2017-01-01
Journal of Virology
Abstract:Interactions between the gp120 and gp41 subunits of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer maintain the metastable unliganded form of the viral spike. Binding of gp120 to the receptor, CD4, changes the Env conformation to promote gp120 interaction with the second receptor, CCR5 or CXCR4. CD4 binding also induces the transformation of Env into the prehairpin intermediate, in which the gp41 heptad repeat 1 (HR1) coiled coil is assembled at the trimer axis. In nature, HIV-1 Envs must balance the requirements to maintain the noncovalent association of gp120 with gp41 and to evade the host antibody response with the need to respond to CD4 binding. Here we show that the gp41 HR1 region contributes to gp120 association with the unliganded Env trimer. Changes in particular amino acid residues in the gp41 HR1 region decreased the efficiency with which Env moved from the unliganded state. Thus, these gp41 changes decreased the sensitivity of HIV-1 to cold inactivation and ligands that require Env conformational changes to bind efficiently. Conversely, these gp41 changes increased HIV-1 sensitivity to small-molecule entry inhibitors that block Env conformational changes induced by CD4. Changes in particular gp41 HR1 amino acid residues can apparently affect the relative stability of the unliganded state and CD4-induced conformations. Thus, the gp41 HR1 region contributes to the association with gp120 and regulates Env transitions from the unliganded state to downstream conformations.IMPORTANCE The development of an efficient vaccine able to prevent HIV infection is a worldwide priority. Knowledge of the envelope glycoprotein structure and the conformational changes that occur after receptor engagement will help researchers to develop an immunogen able to elicit antibodies that block HIV-1 transmission. Here we identify residues in the HIV-1 transmembrane envelope glycoprotein that stabilize the unliganded state by modulating the transitions from the unliganded state to the CD4-bound state.
-
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.
H Ji,W Shu,F T Burling,S Jiang,M Lu
DOI: https://doi.org/10.1128/JVI.73.10.8578-8586.1999
IF: 6.549
1999-01-01
Journal of Virology
Abstract:The gp41 envelope protein of human immunodeficiency virus type 1 (HIV-1) contains an alpha-helical core structure responsible for mediating membrane fusion during viral entry. Recent studies suggest that a conserved hydrophobic cavity in the coiled coil of this core plays a distinctive structural role in maintaining the fusogenic conformation of the gp41 molecule. Here we investigated the importance of this cavity in determining the structure and hiological activity of the gp41 core by using the N34(L6)C28 model. The high-resolution crystal structures of N34(L6)C28 of two HIV-1 gp41 fusion-defective mutants reveal that each mutant sequence is accommodated in the six-helix bundle structure by forming the cavity with different sets of atoms. Remarkably, the mutant N34(L6)C28 cores are highly effective inhibitors of HIV-1 infection, with 5- to 16-fold greater activity than the wild-type molecule. The enhanced inhibitory activity by fusion-defective mutations correlates with local structural perturbations close to the cavity that destabilize the six-helix bundle, Taken together, these results indicate that the conserved hydrophobic coiled-coil cavity in the gp41 core is critical for HIV-1 entry and its inhibition and provides a potential antiviral drug target.
-
Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.
W. Shu,J. Liu,H. Ji,L. Rading,S. Jiang,M. Lu
DOI: https://doi.org/10.1021/bi9921687
1999-01-01
Abstract:The HIV-1 gp41 envelope protein mediates membrane fusion that leads to virus entry into the cell. The core structure of fusion-active gp41 is a six-helix bundle in which an N-terminal three-stranded coiled coil is surrounded by a sheath of antiparallel C-terminal helices. A conserved glutamine (Gln 652) buried in this helical interface replaced by leucine increases HIV-1 infectivity. To define the basis for this enhanced membrane fusion activity, we investigate the role of the Gln 652 to Leu substitution on the conformation, stability, and biological activity of the N34(L6)C28 model of the gp41 ectodomain core. The 2.0 A resolution crystal structure of the mutant molecule shows that the Leu 652 side chains make prominent contacts with hydrophobic grooves on the surface of the central coiled coil. The Gln 652 to Leu mutation leads to a marginal stabilization of the six-helix bundle by -0.8 kcal/mol, evaluated from thermal unfolding experiments. Strikingly, the mutant N34(L6)C28 peptide is a potent inhibitor of HIV-1 infection, with 10-fold greater activity than the wild-type molecule. This inhibitory potency can be traced to the corresponding C-terminal mutant peptide that likely has greater potential to interact with the coiled-coil trimer. These results provide strong evidence that conserved interhelical packing interactions in the gp41 core are important determinants of HIV-1 entry and its inhibition. These interactions also offer a test-bed for the development of more potent analogues of gp41 peptide inhibitors.
-
Role of the Fusion Peptide and Membrane-Proximal Domain in HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion
Antony S. Dimitrov,Satinder S. Rawat,Shibo Jiang,Robert Blumenthal
DOI: https://doi.org/10.1021/bi035154g
IF: 3.321
2003-01-01
Biochemistry
Abstract:The N-terminal fusion peptide and the interfacial sequence preceding the transmembrane anchor of HIV-1 gp41 are required for viral fusion. Studies with synthetic peptides indicated that these regions function by destabilizing membranes, which is regarded as a crucial step in the membrane fusion reaction. However, it is not clear whether membrane destabilization is induced by these sequences in the intact gp41. We address this question by examining fusion and destabilization of membranes expressing HIV-1(IIIB) wild-type Env and two mutant Envs. (1) A Glu residue at position 2 of the gp41 fusion peptide is substituted for Va1 (V2E) to produce one Mutant. (2) Residues 665-682 in the membrane-proximal domain are deleted to form the other. The process of membrane destabilization was monitored by the influx of Sytox, an impermeant fluorescent dye, into the Env-expressing cells following the interaction with CD4-CXCR4 complexes, and fusion was monitored by observing dye transfer between Env-expressing cells and appropriate target cells. We also monitored the conformational changes in the Envs following their interactions with CD4 and CXCR4 by immunofluorescence using an anti-gp41 mAb that reacts with the six-helix bundle. In contrast to the wild type, both Env mutants did not mediate cell fusion. The V2E Env did not mediate membrane destabilization. However, the Env with an unmodified fusion peptide but with a deletion of residues 665-682 in the membrane-proximal domain did mediate membrane destabilization. The wild type and both mutant Envs undergo conformational changes detected by the anti-gp41 six-helix bundle mAbs. Our results Suggest that in intact HIV-1 Env the membrane-proximal domain is not required for membrane perturbations, but rather enables the bending of gp41 that is required for viral and target membranes to come together. Moreover, the observation that the Delta665-683 Env self-inserts its fusion peptide but does not cause fusion suggests that self-insertion of the fusion peptide is not Sufficient for HIV-1 Env-mediated fusion.
-
N- and C-domains of HIV-1 gp41: mutation, structure and functions.
X N Dong,Y Xiao,M P Dierich,Y H Chen
DOI: https://doi.org/10.1016/S0165-2478(00)00302-3
IF: 4.23
2001-01-01
Immunology Letters
Abstract:Recent studies demonstrated that the N- and C-domains of HIV-1 gp41 is involved in virus-mediated membrane fusion resulting in HIV-entry into the target cells. Up to now, viral mutation baffled many scientists to develop effective vaccines and drugs against HIV-1. To acquire more information of mutation of gp41 and to reveal the relationship of structure and function of the N- and C-domains, we compared and analyzed amino acid sequences of the gp41 ectodomain (aa 512-681) of 862 isolates from most HIV-1 clades (including A, B, C, D, E, F, G, H, I, J and O clades). A consensus sequence of the ectodomain with the highest frequency emerging on each position is constituted. The fusion domain and the N-domain belong to the most conserved regions in gp41, and most variable residues assemble partial to the C terminal of gp41. The hydrophobicity of each position is also calculated. The a and d positions in the N-domain for maintaining stabilization of the trimeric coiled coil interactions are highly conservative, and the e and g positions in the C-domain to retain the interaction show also highly conservative. The strange high conservation of the c residues may have an implication in the coiled coil structure. The highly conserved residues form the lining of the hydrophobic cavity and the deep cavity is an ideal target for small molecular inhibitors. On the C-terminal of the C-domain there is a highly conserved segment GIVQQQ. They are intimately involved in forming the three interfaces between neighboring helices. The function of the N- and C-domains, such as binding to the potential cellular receptor and inducing protective activities, are also discussed. These studies on the mutation, structure and functions of the N- and C-domains suggested that both domains become a new focus to develop effective vaccine and antiviral drugs in the new strategies.
-
The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.
Jing-He Huang,Heng-Wen Yang,Shuwen Liu,Jing Ll,Shibo Jiang,Ying-Hua Chen
DOI: https://doi.org/10.1042/bj20061275
IF: 3.766
2007-01-01
Biochemical Journal
Abstract:The HIV-1 gp41 (glycoprotein 41) core plays a critical role in fusion between the viral and target cell membranes. We previously identified a gp41 core-binding motif, HXXNPF, by screening the phage display peptide libraries. In the present study, we elucidated the mechanism of action of HXXNPF motif-containing molecules of different sizes, including the phage clone L7.8 (a selected positive phage clone), L7.8-g3p* (a 10-kDa fragment of the gene 3 protein) and JCH-4 (a peptide containing 13 residues of L7.8-g3p*), regarding their respective binding abilities to the six-helix bundle and inhibition on syncytium formation at different temperatures. We found that all of the HXXNPF motif-containing molecules could bind to the gp41 core, and that their binding sites may be located in the N-helix domain. L7.8-g3p* and JCH-4 effectively inhibited HIV-1 Env (envelope glycoprotein)-mediated syncytium formation at 37 degrees C, while the phage clone L7.8 showed no inhibition under the same conditions. However, at suboptimal temperature (31.5 degrees C), all of these HXXNPF motif-containing molecules were capable of inhibiting syncytium formation. These results suggest that these HXXNPF motif-containing molecules mainly bind to the gp41 core and stop the fusion process mediated by the fusion-active core, resulting in inhibition of HIV-1 fusion and entry. The HXXNPF motif-containing molecules may be used as probes for studying the role of the HIV-1 gp41 core in the late stage of the membrane-fusion process.
-
Conserved Salt Bridge Between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 Gp41 Core Structure is Critical for Virus Entry and Inhibition
Yuxian He,Shuwen Liu,Jingjing Li,Hong Lu,Zhi Qi,Zhonghua Liu,Asim K. Debnath,Shibo Jiang
DOI: https://doi.org/10.1128/jvi.01060-08
IF: 6.549
2008-01-01
Journal of Virology
Abstract:ABSTRACT The fusogenic human immunodeficiency virus type 1 (HIV-1) gp41 core structure is a stable six-helix bundle formed by its N- and C-terminal heptad repeat sequences. Notably, the negatively charged residue Asp632 located at the pocket-binding motif in the C-terminal heptad repeat interacts with the positively charged residue Lys574 in the pocket formation region of the N-terminal heptad repeat to form a salt bridge. We previously demonstrated that the residue Lys574 plays an essential role in six-helix bundle formation and virus infectivity and is a key determinant of the target for anti-HIV fusion inhibitors. In this study, the functionality of residue Asp632 has been specifically characterized by mutational analysis and biophysical approaches. We show that Asp632 substitutions with positively charged residues (D632K and D632R) or a hydrophobic residue (D632V) could completely abolish Env-mediated viral entry, while a protein with a conserved substitution (D632E) retained its activity. Similar to the Lys574 mutations, nonconserved substitutions of Asp632 also severely impaired the α-helicity, stability, and conformation of six-helix bundles as shown by N36 and C34 peptides as a model system. Furthermore, nonconserved substitutions of Asp632 significantly reduced the potency of C34 to sequestrate six-helix bundle formation and to inhibit HIV-1-mediated cell-cell fusion and infection, suggesting its importance for designing antiviral fusion inhibitors. Taken together, these data suggest that the salt bridge between the N- and C-terminal heptad repeat regions of the fusion-active HIV-1 gp41 core structure is critical for viral entry and inhibition.
-
Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55(gag) precursor protein
MA Egan,LM Carruth,JF Rowell,XF Yu,RF Siliciano
DOI: https://doi.org/10.1128/JVI.70.10.6547-6556.1996
IF: 6.549
1996-01-01
Journal of Virology
Abstract:The mechanisms involved in the incorporation of viral glycoproteins into virions are incompletely understood. For retroviruses, incorporation may involve interactions between the Gag proteins of these viruses and the cytoplasmic domains of the relevant envelope (Env) glycoproteins. Recent studies have identified within the cytoplasmic tail of the human immunodeficiency virus type 1 (HIV-1) Env protein a tyrosine-containing internalization motif similar to those found in the cytoplasmic domains of certain cell surface proteins that undergo rapid constitutive endocytosis in clathrin-coated pits. Given that surface expression of the HIV-1 Env protein is essential for the production of infectious virus, the presence Of this internalization motif is surprising. We show here that in contrast to the rapid rate of Fm protein internalization observed in cells expressing the Env protein in the absence of other HIV-1 proteins, the rate of internalization of Env protein from the surfaces of HIV-l-infected cells is extremely slow. The presence of the Pr55(gag) precursor protein is necessary and sufficient for inhibition of Env protein internalization, while a mutant Pr55(gag) that is incapable of mediating Env incorporation into virions is also unable to inhibit endocytosis of the Env protein. The failure of the Env protein to undergo endocytosis from the surface of an HIV-1-infected cell may reflect the fact that the proposed interaction of the matrix domain of the Gag protein with Env during assembly prevents the interaction of Env with host adaptin molecules that recruit plasma membrane molecules such as the transferrin receptor into clathrin-coated pits. When the normal ratio of Gag and Env proteins in the infected cells is altered by overexpression of Env protein, this mechanism allows removal of excess Env protein from the cell surface. Taken together, these results suggest that a highly conserved system to reduce surface levels of the Env protein functions to remove Env protein that is not associated with Gag and that is therefore not destined for incorporation into virions. This mechanism for the regulation of surface levels of Fm protein may protect infected cells from Env-dependent cytopathic effects or Env-specific immune responses.
-
Asymmetric Structures and Conformational Plasticity of the Uncleaved Full-Length Human Immunodeficiency Virus Envelope Glycoprotein Trimer.
Shijian Zhang,Kunyu Wang,Wei Li Wang,Hanh T. Nguyen,Shuobing Chen,Maolin Lu,Eden P. Go,Haitao Ding,Robert T. Steinbock,Heather Desaire,John C. Kappes,Joseph Sodroski,Youdong Mao
DOI: https://doi.org/10.1128/jvi.00529-21
IF: 6.549
2021-01-01
Journal of Virology
Abstract:The functional human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer [(gp120/gp41)3] is produced by cleavage of a conformationally flexible gp160 precursor. gp160 cleavage or the binding of BMS-806, an entry inhibitor, stabilizes the pretriggered, "closed" (state 1) conformation recognized by rarely elicited broadly neutralizing antibodies. Poorly neutralizing antibodies (pNAbs) elicited at high titers during natural infection recognize more "open" Env conformations (states 2 and 3) induced by binding the receptor, CD4. We found that BMS-806 treatment and cross-linking decreased the exposure of pNAb epitopes on cell surface gp160; however, after detergent solubilization, cross-linked and BMS-806-treated gp160 sampled non-state-1 conformations that could be recognized by pNAbs. Cryo-electron microscopy of the purified BMS-806-bound gp160 revealed two hitherto unknown asymmetric trimer conformations, providing insights into the allosteric coupling between trimer opening and structural variation in the gp41 HR1N region. The individual protomer structures in the asymmetric gp160 trimers resemble those of other genetically modified or antibody-bound cleaved HIV-1 Env trimers, which have been suggested to assume state-2-like conformations. Asymmetry of the uncleaved Env potentially exposes surfaces of the trimer to pNAbs. To evaluate the effect of stabilizing a state-1-like conformation of the membrane Env precursor, we treated cells expressing wild-type HIV-1 Env with BMS-806. BMS-806 treatment decreased both gp160 cleavage and the addition of complex glycans, implying that gp160 conformational flexibility contributes to the efficiency of these processes. Selective pressure to maintain flexibility in the precursor of functional Env allows the uncleaved Env to sample asymmetric conformations that potentially skew host antibody responses toward pNAbs. IMPORTANCE The envelope glycoprotein (Env) trimers on the surface of human immunodeficiency virus (HIV-1) mediate the entry of the virus into host cells and serve as targets for neutralizing antibodies. The functional Env trimer is produced by cleavage of the gp160 precursor in the infected cell. We found that the HIV-1 Env precursor is highly plastic, allowing it to assume different asymmetric shapes. This conformational plasticity is potentially important for Env cleavage and proper modification by sugars. Having a flexible, asymmetric Env precursor that can misdirect host antibody responses without compromising virus infectivity would be an advantage for a persistent virus like HIV-1.
-
Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain is Critical for Six-helix Bundle Stability and Virus Entry*
Yuxian He,Shuwen Liu,Weiguo Jing,Hong Lu,Dongmei Cai,Darin Jeekin Chin,Asim K. Debnath,Frank Kirchhoff,Shibo Jiang
DOI: https://doi.org/10.1074/jbc.m703781200
IF: 5.485
2007-01-01
Journal of Biological Chemistry
Abstract:The fusion-active HIV-1 gp41 core structure is a stable six-helix bundle (6-HB) formed by its N- and C-terminal heptad-repeat sequences (NHR and CHR). A highly conserved, deep hydrophobic cavity on the surface of the N-helical trimer is important for stability of the 6-HB and serves as an ideal target for developing anti-human immunodeficiency virus (HIV) fusion inhibitors. We have recently identified several small molecule HIV-1 fusion inhibitors that bind to the gp41 cavity through hydrophobic and ionic interactions and block the gp41 6-HB formation. Molecular docking analysis reveals that these small molecules fit inside the hydrophobic cavity and interact with positively charged residue Lys574 to form a conserved salt bridge. In this study, the functionality of Lys574 has been finely characterized by mutational analysis and biophysical approaches. We found that substitutions of Lys574 with non-conserved residues (K574D, K574E, and K574V) could completely abolish virus infectivity. With a set of wild-type and mutant N36 peptides derived from the NHR sequence as a model, we demonstrated that non-conservative Lys574 substitutions severely impaired the stability and conformation of 6-HBs as detected by circular dichroism spectroscopy, native polyacrylamide gel electrophoresis, and enzyme-linked immunosorbent assay. The binding affinity of N36 mutants bearing non-conservative Lys574 substitutions to the peptide C34 derived from the CHR sequence dramatically decreased as measured by isothermal titration calorimetry. These substitutions also significantly reduced the potency of N-peptides to inhibit HIV-1 infection. Collectively, these data suggest that conserved Lys574 plays a critical role in 6-HB formation and HIV-1 infectivity, and may serve as an important target for designing anti-HIV drugs.
-
Progress in the structure and function of human immunodeficiency virus type 1 gp41
YAO Qian-Qian,LV Jun,YE Rong
DOI: https://doi.org/10.3969/j.issn.1673-6184.2011.04.008
2011-01-01
Abstract:Entrance of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by envelope glycoprotein (Env), which contains a receptor-binding unit, gp120, and a membrane-fusion unit, gp41. HIV-1 gp41 consists of three major functional regions: ectodomain, membrane-spanning domain (MSD) and endodomain. The ectodomain is the structural basis for membrane fusion during viral infection; the hydrophobic residues of the MSD anchor Env to the bilayer membrane; and the endodomain plays multiple functions in viral infection, replication, and assembly. The most important motifs in the endodomain are three lentivirus lytic peptides (LLP 1-3), two Tyr-contained motifs (Y712XXL and Y802W803), and a di-leucine motif (LL856/857). Additionally, the topological change of the endodomain such as those at Kennedy epitope, indicates that there are interactions among the three regions of gp41. Progress in understanding the function-structure relationship of gp41 not only improves our knowledge about replication and pathogenesis of HIV-1 but also provides some insight into the development of new antiviral drugs.
-
Evaluation of the Contribution of the Transmembrane Region to the Ectodomain Conformation of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein
Hanh T. Nguyen,Navid Madani,Haitao Ding,Emerald Elder,Amy Princiotto,Christopher Gu,Patrice Darby,James Alin,Alon Herschhorn,John C. Kappes,Youdong Mao,Joseph G. Sodroski
DOI: https://doi.org/10.1186/s12985-017-0704-x
IF: 5.916
2017-01-01
Virology Journal
Abstract:Background: The human immunodeficiency virus (HIV-1) envelope glycoprotein (Env), a Type 1 transmembrane protein, assembles into a trimeric spike complex that mediates virus entry into host cells. The high potential energy of the metastable, unliganded Env trimer is maintained by multiple non-covalent contacts among the gp120 exterior and gp41 transmembrane Env subunits. Structural studies suggest that the gp41 transmembrane region forms a left-handed coiled coil that contributes to the Env trimer interprotomer contacts. Here we evaluate the contribution of the gp41 transmembrane region to the folding and stability of Env trimers.Methods: Multiple polar/charged amino acid residues, which hypothetically disrupt the stop-transfer signal, were introduced in the proposed lipid-interactive face of the transmembrane coiled coil, allowing release of soluble cleavage-negative Envs containing the modified transmembrane region (TMmod). We also examined effects of cleavage, the cytoplasmic tail and a C-terminal fibritin trimerization (FT) motif on oligomerization, antigenicity and functionality of soluble and membrane-bound Envs.Results: The introduction of polar/charged amino acids into the transmembrane region resulted in the secretion of soluble Envs from the cell. However, these TMmod Envs primarily formed dimers. By contrast, control cleavage-negative sgp140 Envs lacking the transmembrane region formed soluble trimers, dimers and monomers. TMmod and sgp140 trimers were stabilized by the addition of a C-terminal FT sequence, but still exhibited carbohydrate and antigenic signatures of a flexible ectodomain structure. On the other hand, detergent-solubilized cleaved and uncleaved Envs isolated from the membranes of expressing cells exhibited "tighter" ectodomain structures, based on carbohydrate modifications. These trimers were found to be unstable in detergent solutions, but could be stabilized by the addition of a C-terminal FT moiety. The C-terminal FT domain decreased Env cleavage and syncytium-forming ability by approximately three-fold; alteration of the FT trimerization interface restored Env cleavage and syncytium formation to near-wild-type levels.Conclusion: The modified transmembrane region was not conducive to trimerization of soluble Envs. However, for HIV-1 Env ectodomains that are minimally modified, membrane-anchored Envs exhibit the most native structures and can be stabilized by appropriately positioned FT domains.
-
Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.
Kristin Eissmann,Sebastian Mueller,Heinrich Sticht,Susan Jung,Peng Zou,Shibo Jiang,Andrea Gross,Jutta Eichler,Bernhard Fleckenstein,Heide Reil
DOI: https://doi.org/10.1371/journal.pone.0054452
IF: 3.7
2013-01-01
PLoS ONE
Abstract:A strategy for antiviral drug discovery is the elucidation and imitation of viral interference mechanisms. HIV-1 patients benefit from a coinfection with GB Virus C (GBV-C), since HIV-positive individuals with long-term GBV-C viraemia show better survival rates than HIV-1 patients without persisting GBV-C. A direct influence of GBV-C on HIV-1 replication has been shown in coinfection experiments. GBV-C is a human non-pathogenic member of the flaviviridae family that can replicate in T and B cells. Therefore, GBV-C shares partly the same ecological niche with HIV-1. In earlier work we have demonstrated that recombinant glycoprotein E2 of GBV-C and peptides derived from the E2 N-terminus interfere with HIV entry. In this study we investigated the underlying mechanism. Performing a virus-cell fusion assay and temperature-arrested HIV-infection kinetics, we provide evidence that the HIV-inhibitory E2 peptides interfere with late HIV-1 entry steps after the engagement of gp120 with CD4 receptor and coreceptor. Binding and competition experiments revealed that the N-terminal E2 peptides bind to the disulfide loop region of HIV-1 transmembrane protein gp41. In conjunction with computational analyses, we identified sequence similarities between the N-termini of GBV-C E2 and the HIV-1 glycoprotein gp120. This similarity appears to enable the GBV-C E2 N-terminus to interact with the HIV-1 gp41 disulfide loop, a crucial domain involved in the gp120-gp41 interface. Furthermore, the results of the present study provide initial proof of concept that peptides targeted to the gp41 disulfide loop are able to inhibit HIV fusion and should inspire the development of this new class of HIV-1 entry inhibitors.
-
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.
Melody R Davis,Jiyang Jiang,Jing Zhou,Eric O Freed,Christopher Aiken
DOI: https://doi.org/10.1128/JVI.80.5.2405-2417.2006
IF: 6.549
2006-01-01
Journal of Virology
Abstract:The Gag protein of human immunodeficiency virus type 1 (HIV-1) associates with the envelope protein complex during virus assembly. The available evidence indicates that this interaction involves recognition of the gp41 cytoplasmic tail (CT) by the matrix protein (MA) region of Pr55(Gag). Here we show that substitution of Asp for Leu at position 49 (L49D) in MA results in a specific reduction in particle-associated gp120 without affecting the levels of gp41. Mutant virions were markedly reduced in single-cycle infectivity despite a relatively modest defect in fusion with target cells. Studies with HIV-1 particles containing decreased levels of envelope proteins suggested that the L49D mutation also inhibits a postentry step in infection. Truncation of the gp41 tail, or pseudotyping by vesicular stomatitis virus glycoprotein, restored both the fusion and infectivity of L49D mutant virions to wild-type levels. Truncation of gp41 also resulted in equivalent levels of gp120 on particles with and without the MA mutation and enhanced the replication of the L49D mutant virus in T cells. The impaired fusion and infectivity of L49D mutant particles were also complemented by a single point mutation in the gp41 CT that disrupted the tyrosine-containing endocytic motif. Our results suggest that an altered interaction between the MA domain of Gag and the gp41 cytoplasmic tail leads to dissociation of gp120 from gp41 during HIV-1 particle assembly, thus resulting in impaired fusion and infectivity.
-
Biological Function of H1V-1 Transmembrane Protein Gp41
Yinghua Chen,Manfred P. Dierich
DOI: https://doi.org/10.1007/bf02883408
1998-01-01
Chinese Science Bulletin
Abstract:Since 1992, the study of biological functions of HIV-1 gp41 has made great progress. Experimental evidence from several research groups demonstrated that gp41 has a putative cellular receptor. A recombinant soluble gp41 (aa539–684) and gp41 immunosuppressive peptide (aa583–599) could bind to human B lymphocytes and monocytes, but weakly bind to T lymphocytes. It was found that gp41 contains two cellular binding sites (aa583–599 and 641–675). GP41 could selectively inhibit cell proliferation of human T, B lymphocytes and monocytes, enhance human MHC class I, II and ICAM-1 molecule expression on cell surface. Gp41 binding proteins and a monoclonal antibody against the first binding site could inhibit this modulation effect. Amino acid sequence homology exists between gp41 and human type I interferons, and the homologous region is located in the first binding site on gp41 and in the receptor binding site on type I interferons. Studies in other groups indicate that both binding sites in gp41 may be associated with HIV infection of cells. Peptides containing two binding sites could respectively inhibit HIV infection of cells. A monoclonal antibody recognizing the second binding site could neutralize lab-strains and recently separated strains of HIV-1. Besides, antibodies against two regions (homologous with gp41 binding sites) of SIV transmembrane protein gp32 could protect macaques from SIV infection. These results suggest that the study of gp41 binding sites and cellular receptor could contribute to understanding the mechanism of HIV infection and to developing HIV vaccine and anti-HIV drugs.
-
HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.
Chungen Pan,Shuwen Liu,Shibo Jiang
DOI: https://doi.org/10.1016/s0929-6646(10)60029-0
IF: 3.871
2010-01-01
Journal of the Formosan Medical Association
Abstract:Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conformational changes in the gp41 transmembrane subunit. These changes include insertion of fusion peptide into the target cell membrane and association of C-heptad repeat (CHR) peptide with the N-heptad repeat (NHR) trimer, a pre-hairpin fusion intermediate. A stable six-helix bundle core is then formed, bringing the viral envelope and target cell membrane into close proximity for fusion. Peptides derived from the CHR region, such as T20 and C34, inhibit HIV-1 fusion by interacting with the gp41 fusion intermediate. A number of anti-HIV-1 peptides and small molecule compounds targeting the gp41 NHR-trimer have been identified. By combining HIV fusion/entry inhibitors targeting different sites in the gp41 fusion intermediate, a potent synergistic effect takes place, resulting in a potential new therapeutic strategy for the HIV infection/AIDS. Here, we present an overview of the current development of anti-HIV drugs, particularly those targeting the gp41 fusion intermediate.